Clinical trials
Cutaneous T Cell Lymphoma clinical trials
Below are recruiting cutaneous t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Aurora, ColoradoAges birth–38 years - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New Haven, ConnecticutAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT05956041RecruitingPhase 2
Pembrolizumab and mogamulizumab for advanced relapsed skin lymphoma
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Ann Arbor, MichiganAges 18 years+ - NCT05820841RecruitingPhase 3
Acalabrutinib plus R-miniCHOP for untreated lymphoma in older adults
This study tests whether adding acalabrutinib to a reduced-strength chemotherapy plan (R-miniCHOP) works better and is safer for older adults with newly diagnosed diffuse large B-cell lymphoma. It may help you get a more effective treatment while using a dosing approach meant for people who may not tolerate full-strength therapy.
Homburg, SaarlandAges 61 years+ - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+ - NCT05475925RecruitingPhase 1/Phase 2
Test drug DR-01 for specific blood cancer types
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05463263RecruitingPhase 1/Phase 2
Study drug for adults with relapsed or treatment-resistant lymphomas
This Phase 1/2 study tests dencatistat (STP938) to treat adults whose B-cell or T-cell lymphoma has come back or not responded to treatment. It looks at safety, the best dose, and whether it can shrink tumors or improve disease control when standard options have not helped.
Denver, ColoradoAges 18 years+ - NCT00177268Recruiting
Collecting blood and tissue samples in skin diseases research
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
New treatment for blood cancers that have returned
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT04930653RecruitingPhase 2
Photopheresis plus mogamulizumab for advanced skin lymphoma
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
Scottsdale, ArizonaAges 18 years+ - NCT04848064RecruitingPhase 1
Natural killer cells plus mogamulizumab for skin lymphoma
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
Columbus, OhioAges 18 years+ - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Scottsdale, ArizonaAges 18 years+ - NCT04045470Recruiting
Skin-device test to find drugs for T-cell lymphoma lesions
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
Boston, MassachusettsAges 18 years+ - NCT03932279Recruiting
Study skin microbiome in certain skin diseases
This study looks at the bacteria (microbiome) living on the skin in people with specific skin conditions, and in healthy volunteers. The results may help researchers understand what skin microbes have to do with these diseases.
Chicago, IllinoisAges 18–89 - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Duarte, CaliforniaAges 18 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT01087333Recruiting
Share blood samples to help study blood cancers and treatments
This study collects human samples (like blood or other specimens) to learn more about hairy cell leukemia and other leukemias. It also helps researchers develop new lab-made immune-based medicines for cancer treatment.
Bethesda, MarylandAges 18 years+ - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cutaneous t cell lymphoma?
- Yes. Clin2 currently lists 93 recruiting cutaneous t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cutaneous t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cutaneous t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.